PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Early Response to Neoadjuvant Lapatinib Plus Trastuzumab in Stage I to IIIA HER2-positive Breast Cancer

Trial Profile

PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Early Response to Neoadjuvant Lapatinib Plus Trastuzumab in Stage I to IIIA HER2-positive Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Letrozole; Paclitaxel; Tamoxifen
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms PAMELA
  • Most Recent Events

    • 31 Oct 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.
    • 12 Oct 2017 Results (n=213) of study developing and validating a tool to predict response by assessing association between pathological response and early changes in tumor infiltrating lymphocytes using patient data from NCT01973660 and NCT00524303 trials published in the Annals of Oncology
    • 12 Sep 2017 Results assessing tumor-infiltrating lymphocytes in her2-positive early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy, were presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top